Moraxella catarrhalis comprise the most common causative agents of respiratory tract infections (RTIs). Resistance to penicillin and other β-lactam agents commonly used as empirical therapies to treat RTIs is an established concern. This has prompted the development of new oral agents that can be used to treat RTIs in both adult and paediatric patients. Faropenem, an investigational compound, the first in the furanem class of compounds intended for oral administration and sharing structural similarities with β-lactams, has been shown to exhibit broad-spectrum bactericidal activity, 1 including activity against S. pneumoniae that are resistant to other agents. 2, 3 We tested faropenem and comparator β-lactam agents against clinical isolates of S. pneumoniae (n = 1870), H. influenzae (n = 1995) and M. catarrhalis (n = 649) collected during the 2000-2001 respiratory season.
(127 β-lactamase-positive, eight β-lactamase-negative) M. catarrhalis were collected from the UK. Isolates were submitted to a central laboratory (Focus Technologies, Herndon, VA, USA), subcultured on to blood (S. pneumoniae and M. catarrhalis) or chocolate (H. influenzae) agar and reidentified using standard methods. β-Lactamase production in H. influenzae and M. catarrhalis was determined using nitrocefin (BBL DrySlide Nitrocefin; Becton Dickinson, Sparks, MD, USA). All isolates were tested by broth microdilution, in accordance with the NCCLS, 4 against penicillin (S. pneumoniae only), ampicillin (H. influenzae and M. catarrhalis only), co-amoxiclav, cefaclor, cefuroxime, cefdinir, ceftriaxone and faropenem using dried microdilution panels (TREK Diagnostics, Westlake, OH, USA). MICs were interpreted according to the NCCLS 2002 published breakpoints. 5 Table 1 illustrates the activity in vitro of faropenem and comparator β-lactam agents against S. pneumoniae, H. influenzae and M. catarrhalis by country. Penicillin resistance among S. pneumoniae ranged from 1.8% (9/506) among isolates collected in Germany to 28.0% (75/268) among isolates collected in Spain. There was a high level of cross-resistance between penicillin and other β-lactam agents, as the MIC 90 of each agent showed a significant increase between penicillinsusceptible and -resistant isolates. Faropenem MIC 90 s were higher in countries with >18% penicillin resistance (France, Greece, Spain: MIC 90 s, 0.5-1 mg/L), compared with countries with lower prevalences of penicillin resistance (Germany, Italy, UK: MIC 90 s, 0.015-0.03 mg/L). Faropenem showed the highest activity against penicillin-resistant S. pneumoniae of all the β-lactams tested with MIC 90 s of 0.5-1 mg/L in all countries; at least two-fold lower than co-amoxiclav (MIC 90 s, 2-8 mg/L), and equal to or lower than ceftriaxone (MIC 90 s, 1-2 mg/L). Cefaclor, cefdinir and cefuroxime were not active against penicillin-resistant S. pneumoniae in any of the countries surveyed. β-Lactamase production among H. influenzae ranged from 6.2% (4/65) among the isolates collected in Greece to 33.1% (91/275) among the isolates collected in France. Faropenem activity was unaffected by β-lactamase production, since faropenem MIC distributions (data not shown) and MIC 90 s (0.5-1 mg/L) in each country were equivalent for both β-lactamase-positive and -negative isolates.
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β-Lactamase production among M. catarrhalis was >94% in all countries. Faropenem MIC 90 s were 0.5 mg/L in all countries and were comparable to those of co-amoxiclav (0.25 mg/L), cefdinir (0.25 mg/L), cefaclor (1 mg/L), cefuroxime (2 mg/L) and ceftriaxone (0.5 mg/L). All β-lactams showed equivalent MIC 90 s between countries, which were attributed to similar rates of β-lactamase production in the countries surveyed.
Penicillin-resistant S. pneumoniae was 10.6% (199/1870 isolates) overall, comparable to the 1999 SENTRY Antimicrobial Program (10.4%). 6 Despite this apparent levelling off in the prevalence of penicillin-resistant S. pneumoniae, the current levels of resistance compromise the efficacy of penicillin and some orally available cephalosporins. Despite a reduction in the activity of faropenem associated with resistance to penicillin, MIC 90 s of ≤1 mg/L were reported for all countries, below the tentative susceptible breakpoint (≤2 mg/L). Using this breakpoint, 99.9% of S. pneumoniae, 99.8% of H. influenzae and 100% of M. catarrhalis were susceptible to faropenem. From this study, faropenem demonstrates encouraging activity against contemporary European isolates of these respiratory pathogens and warrants further study. 
